A Phase 1 Trial of RO5126766 (CH5126766) in Patients With Advanced KRAS-Mutant Lung Adenocarcinomas
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2018
At a glance
- Drugs RG 7304 (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2018 Status changed from not yet recruiting to recruiting.
- 02 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
- 27 Sep 2018 New trial record